Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

responsive web design (RWD)

- PMLiVE

Happy accidents

A happy collision in market access

ISPOR 2023: Developing Fit-for-Purpose External Control Arms to Optimize Submissions to Regulatory and Health Technology Assessment Agencies

Genesis Research Group

RPR: an agile, on-demand platform that provides clients with faster, higher-quality insights via direct, automated stakeholder engagement.

Genesis Research Group

Accelerating Generation of Payer Insights & Evidence Across the Lifecycle to Achieve Optimal Access

Genesis Research Group

ISPOR Europe: Generating Payer Insights & Evidence: Meeting the Challenges of New Evidence Paradigm

Genesis Research Group

Accelerating Generation of Payer Insights & Evidence Across the Lifecycle to Achieve Optimal Access

Genesis Research Group

Dom Marchant

Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

OPEN Health

- PMLiVE

Pfizer’s pentavalent meningococcal vaccine granted FDA approval

Penbraya helps protect against the five most common meningococcal serogroups

- PMLiVE

Roche to acquire Telavant in deal worth over $7.1bn

The drugmaker will gain access to an experimental treatment for inflammatory bowel disease

- PMLiVE

Merck shares positive results for Keytruda in early-stage breast cancer

Approximately 298,000 people will be diagnosed with breast cancer in the US this year

- PMLiVE

Preparing for the clinical trials of the future

With access to more data than ever before, now is the time for the industry to modernise, become data-led and boost patient experience

- PMLiVE

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Inizio

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links